🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 122 of 857 · Phase 3 first, then by program name

  1. Odronextamab

    Regeneron UK Limited

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  2. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma (FL)

    phase 3 small molecule active

    2 trials

  3. Odronextamab

    Regeneron UK Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  4. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  5. Oka strain varicella attenuated live vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chickenpox Vaccines

    phase 3 mab completed

    1 trial

  6. Olanzapine

    Janssen Cilag International NV

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  7. Olaparib

    AstraZeneca

    Breast Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  8. Olaparib 300mg tablets

    AstraZeneca

    Newly Diagnosed

    phase 3 small molecule active

    1 trial

  9. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  10. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  11. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  12. Olezarsen

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia

    phase 3 small molecule completed

    3 trials

  13. Olezarsen

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  14. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

  15. Olodaterol (BI 1744)

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  16. Olokizumab

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  17. Olokizumab 64 mg SC q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  18. Olokizumab 64mg q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  19. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Aspergillosis

    phase 3 small molecule active

    1 trial

  20. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  21. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.

    phase 3 small molecule active

    1 trial

  22. Olverembatinib

    Ascentage Pharma Group

    Ph+ ALL

    phase 3 small molecule active

    1 trial

  23. Omalizumab (Xolair)

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Urticaria

    phase 3 small molecule completed

    1 trial

  24. Omecamtiv Mecarbil, Omecamtiv Mecarbil, Matching Placebo, Omecamtiv Mecarbil

    Cytokinetics (Ireland) Limited

    Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources